Stratifying the risks of oral anticoagulation in patients with liver disease

Circulation: Cardiovascular Quality and Outcomes

Volumn 7, Issue 3, 2014, Pages 461-467

  Efird, Lydia M ^b   Mishkin, Daniel S ^c   Berlowitz, Dan R ^a,b,d   Ash, Arlene S ^a,b,e   Hylek, Elaine M ^a,b   Ozonoff, Al ^a,f   Reisman, Joel I ^a   Zhao, Shibei ^a   Jasuja, Guneet K ^a,d   Rose, Adam J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Anticoagulants; Hemorrhage; Liver; Warfarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; WARFARIN; SERUM ALBUMIN;

ADVERSE OUTCOME; AGED; ALBUMIN BLOOD LEVEL; ANTICOAGULATION; ARTICLE; BLEEDING; CHRONIC LIVER DISEASE; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD CLOTTING; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; HEMORRHAGE; LIVER DISEASES; METABOLISM; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; CHRONIC DISEASE; CREATININE; FEMALE; HEMORRHAGE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; TREATMENT OUTCOME; WARFARIN;

EID: 84903604362     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.113.000817     Document Type: Article

References (27)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S-198S. (Pubitemid 351892967)
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
5. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
6. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147-156.
7. Villa E, De Maria N. Anticoagulation in cirrhosis. Liver international. 2012;326:878-879.
8. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;1713-1723.
9. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Ame J Gastroenterol. 2009;104:96-101.
10. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8:2182-2191.
11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239. (Pubitemid 23069000)
12. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694. (Pubitemid 41647882)
13. Jasuja GK, Reisman JI, Miller DR, Berlowitz DR, Hylek EM, Ash AS, Ozonoff A, Zhao S, Rose AJ. Identifying major hemorrhage with automated data: results of the veterans affairs study to improve anticoagulation (VARIA). Thrombosis research. 2013;131:31-36.
14. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60:646-649.
15. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia, PA: Saunders; 1964:50-64.
16. Abbasi A, Bhutto AR, Butt N, Lal K, Munir SM. Serum cholesterol: could it be a sixth parameter of Child-Pugh scoring system in cirrhotics due to viral hepatitis? J Coll Physicians Surg Pak. 2012;22:484-487.
17. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-871. (Pubitemid 30169932)
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
19. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173-180.
20. Hannan JL, Radwany SM, Albanese T. In-hospital mortality in patients older than 60 years with very low albumin levels. J Pain Symptom Manage. 2012;43:631-637.
21. Ivanov AI, Korolenko EA, Korolik EV, Firsov SP, Zhbankov RG, Marchewka MK, Ratajczak H. Chronic liver and renal diseases differently affect structure of human serum albumin. Arch Biochem Biophys. 2002;408:69-77. (Pubitemid 36062537)
22. Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care. 2010;14:214.
23. Arnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res. 2006; 118:253-62. (Pubitemid 43816665)
24. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21:154-162.
25. White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P, Gammon H, Schmaltz S, Romano PS. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010;126:61-67.
26. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA. 1997;277:488-494. (Pubitemid 27074334)
27. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med. 1985;313:793-799. (Pubitemid 15232315)